Hutchmed (China) Limited is a commercial-stage biopharmaceutical company engaged in the research, development, manufacture, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates a fully integrated platform that spans discovery, development, manufacturing, and commercialization. Its business segments include the provision of professional scientific and technical support services, as well as sales, distribution, and marketing services to pharmaceutical manufacturers. Hutchmed manufactures and distributes healthcare products, including prescription drugs and consumer health products, in China. The company maintains GMP-standard manufacturing facilities in Suzhou and Shanghai, China, and has qualified drug product sites in Switzerland to support global supply. It serves markets in China, the United States, the European Union, and Japan. Notable products include FRUZAQLA (fruquintinib), ATLED (fanregratinib), and ORPATHYS (savolitinib). The company has established a licensing agreement with GSK for the KRAS-EGFR antibody-targeted therapy conjugate HMPL-A830. Hutchmed has operated in the pharmaceutical sector for over two decades.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage hutch-med.com
Sector Healthcare IR page hutch-med.com
Tags
oncology, immunology, targeted therapies, immunotherapies, cancer treatment, drug discovery, clinical trials, pharmaceutical manufacturing, biopharmaceuticals, precision medicine, FRUZAQLA, fruquintinib, ATLED, fanregratinib, ORPATHYS, savolitinib, TAGRISSO, HMPL-A830, SANOVO, SAFFRON, SACHI, FRESCO-2, ESLIM-01, Sovleplenib
Press page hutch-med.com/news

Metrics

Valuation  
Market cap HK$ 18.73B
Market cap (USD) $ 2.387B
P/E 5.18
PEG —
P/BV 1.91
P/S 4.35
P/OCF -36.92
P/FCF —
Dividend yield —
Turnover / mcap 0.41%
Returns  
ROE 371.5%
ROI 483.3%
ROIC 483.3%
Profit margin 83.4%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 12.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Revenue 548.512M 630.201M 837.999M 426.409M 356.128M 227.976M 204.89M 214.109M 241.203M 216.08M 178.203M
Net profit 456.909M 37.729M 100.78M -360.835M -194.648M -125.73M -106.024M -74.805M -26.737M 11.698M 7.993M
Free cash flow -78.805M -17.436M 186.646M -305.263M -220.624M -70.015M -89.477M -39.211M -13.962M -13.896M -12.709M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015
Share price 13.33 14.41 18.11 14.78 35.08 32.02 25.07 23.09 39.42 13.57 —
Price performance 12m -0.07 -0.2 0.23 -0.58 0.1 0.28 0.09 -0.41 1.9 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 40.8M 38.4M 40.2M 41.4M 46.6M 83.6M 98M 117M 156M 127M
↳ YoY growth +22.4% -5.9% +4.6% +3.1% +12.6% +79.2% +17.2% +19.3% +33.1% -18.5%
↳ 5y CAGR +6.9% +15.4% +20.6% +23.8% +30.3% +22.1%
Borrowings, current (USD) 20M 30M — — — 26.9M — 62.3M 46.7M 49.9M
Borrowings, non-current (USD) 26.8M — 26.7M 26.8M 26.9M — 18.1M 48.2M 59.4M 68.2M
Lease liabilities (USD) — — 6.36M 6.27M 8.85M 12.1M 8.9M 6.79M 7.01M 4.73M
Cash and deposits (USD) 79.4M 85.3M 86M 121M 236M 378M 313M 284M 154M 71.3M
Intangible assets (USD) 469,000 430,000 347,000 275,000 227,000 163,000 85,000 21,000 — 8.94M
Right-of-use assets (USD) — — 5.7M 5.52M 8.02M 11.9M 8.72M 4.67M 4.5M 3.03M
Net debt (borrowings + leases - cash) (USD) -52.6M -55.3M -59.3M -88.1M -200M -339M -286M -166M -40.8M 51.5M
Cash flow detail
Operating cash flow (USD) -9.57M -8.94M -32.8M -80.9M -62.1M -204M -269M 219M 497,000 -64.7M
Purchases of property, plant and equipment (USD) -4.33M -5.02M -6.36M -8.57M -7.95M -16.4M -36.7M -32.6M -17.9M -14.1M
Purchases of intangible assets (USD) — — — — — — — — — -10M
Change in receivables (cash effect) (USD) -7.26M 2.16M -1.56M -1.21M -5.32M -35.6M -14.5M -21.3M -38.5M 28.9M
Change in inventories (cash effect) (USD) -3.43M 1.05M -557,000 -4.22M -3.62M -16M -21.2M 4.14M -772,000 9.54M
Change in payables (cash effect) (USD) 9.82M -11.2M 1.26M -1.66M 7.65M 9.57M 29.9M -32.5M 6.19M 3.01M
Share buybacks (cash effect) (USD) -604,000 -1.37M -5.45M -346,000 -12.9M -27.3M -48.1M -9.07M -36.1M —
Interest paid (cash effect) (USD) -1.57M -763,000 -979,000 -917,000 -815,000 -425,000 -150,000 -421,000 -2.51M -2.52M
Income taxes paid (cash effect) (USD) 2.66M -3.84M -3.75M -3.25M -5.94M -5.01M -18.9M -3.73M -3.59M -62.4M
Operating cash flow before change in receivables (USD) -2.31M -11.1M -31.3M -79.7M -56.8M -169M -254M 241M 39M -93.5M
Free cash flow (OCF - PPE - intangibles) (USD) -13.9M -14M -39.2M -89.5M -70M -221M -305M 187M -17.4M -88.8M
Income detail
Research and development expense (USD) 66.9M 75.5M 114M 138M 175M 299M 387M 302M 212M 148M
↳ 5y CAGR +35.8% +29.8% +34.9% +38.6% +21.5% +8.9% -3.2%
Total comprehensive income (USD) 3.84M -12M -77.9M -108M -106M -164M -369M 94.5M 34.4M 460M
Comprehensive income to owners (USD) 2.41M -17M -80.5M -110M -117M -192M -368M 94.5M 34.3M 459M
Provision for credit losses (USD) 29,000 242,000 21,000 16,000 95,000 16,000 150,000 141,000 70,000 3,000
Credit cost ratio (credit losses / average receivables) (%) 0.1% 0.6% 0.1% 0.0% 0.2% 0.0% 0.2% 0.1% 0.1% 0.0%
Reported Mar 12, 2018 Mar 12, 2018 Mar 3, 2020 Mar 3, 2020 Mar 4, 2021 Mar 3, 2022 Feb 28, 2023 Feb 28, 2024 Mar 19, 2025 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Hutchmed (China) Limited (ticker 13), listed in Hong Kong.

ETFs Holding Hutchmed (China) Limited

ETF Weight in ETF Shares Market value As of
AVEE 0.19% 85,500 $ 250.503K Nov 16, 2026
DFSE 0.02% 28,312 $ 100.848K Nov 12, 2026
DFEM 0.02% 457,074 $ 1.443M Nov 12, 2026
DFAX 0.01% 219,110 $ 685.267K Nov 12, 2026
AVEM 0.00% 317,500 $ 930.23K Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
HCM Common share — US nasdaq 14.63 USD 2026-09-30
HCM Common share — GB lse — —
13 canonical Common share — HK hkex 21.48 HKD 2026-11-19